Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X)

A Safety Open-label Study of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis Disease, an eXtension Study. The EYEGUARD-X Study

The objective of this study is to evaluate long-term safety of gevokizumab in patient with chronic non-infectious uveitis who previously well tolerated the study drug and may benefit from longterm treatment with gevokizumab.

Inclusion Criteria:

• either completed participation to one of the following: CL3-78989-002 open-label extension, or X052130/CL3-78989-005 double-masked period or open-label period, or X052131/CL3-78989-006 double-masked period or open-label period, or currently benefiting from gevokizumab compassionate use after participation in gevokizumab uveitis studies
• Male or female, age ≥18 (or legal age of majority in the country) at selection.
• For subject with reproductive potential, a willingness to use highly effective contraceptive measures

Exclusion Criteria:

• Meeting criteria for discontinuation of any of gevokizumab uveitis previous study.
• Infectious uveitis and masquerade syndrome
• History of severe allergic or anaphylactic reaction to study drug administration during previous study or to gevokizumab or any of its excipient.
• Currently active infectious disease.

Other protocol-defined inclusion/exclusion criteria may apply